Indeed, previous reports have demonstrated that treatment with scaffolding LSD1 inhibitors can disrupt the LSD1 interaction with CoREST and GFI1/1B, thereafter inducing expression of myelo-monocytic differentiation-associated markers (CD86 and CD11b) and acquisition of morphologic differentiation features in AML cells [28, 31–33]. The gene discussed is CD86; the disease is acute myeloid leukemia.